- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CORNERSTONE THERAPEUTICS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 111,50 | -0,05 % | Gilead Sciences, Inc.: Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 | - Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers - - Bulevirtide Data Strengthen Evidence of... ► Artikel lesen | |
| ZOETIS | 63,82 | -0,13 % | ZOETIS INC: Stabile Phase mit klarer Struktur | ||
| INCYTE | 82,74 | +0,88 % | Incyte gibt bekannt, dass mehr als 20 Abstrakte für die Präsentation auf dem Kongress der European Hematology Association (EHA) 2026 angenommen wurden | Daten aus der zulassungsrelevanten Phase-3-Studie "frontMIND" zur Bewertung von Tafasitamab (Monjuvi/Minjuvi) bei der Erstlinienbehandlung des diffusen großzelligen B-Zell-Lymphoms (DLBCL) wurden... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,020 | 0,00 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| AMARIN | 12,600 | +0,80 % | Amarin-Aktionäre lehnen zentrale Anträge ab und schränken Aktienvergütung ein | ||
| ACHIEVE LIFE SCIENCES | 5,100 | +12,33 % | Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma | SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 193,00 | +4,89 % | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 458,20 | +1,60 % | Truist raises Madrigal Pharmaceuticals stock price target on MASH survey | ||
| ANI PHARMACEUTICALS | 67,00 | 0,00 % | ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook | ||
| TALPHERA | 0,750 | -0,66 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 27,810 | +11,42 % | Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Pharmaceuticals Licenses PROTAC Drug, Bristol Myers Squibb Strikes $15.2B Deal | NEW YORK CITY (dpa-AFX) - This week's biotech highlights Lilly's strong Phase 3b maintenance results for Zepbound and Foundaya, Rigel's global license for the first FDA-approved PROTAC therapy... ► Artikel lesen | |
| SAVARA | 4,460 | +2,93 % | Savara Inc - 10-Q, Quarterly Report | ||
| BIODEXA PHARMACEUTICALS | 3,180 | -3,64 % | Biodexa Pharmaceuticals PLC: Biodexa issues letter to Shareholders | May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or... ► Artikel lesen | |
| ARTIVION | 19,200 | -2,04 % | Artivion-Aktionäre bestätigen Direktoren und genehmigen Vorstandsvergütung | ||
| HERON THERAPEUTICS | 0,729 | 0,00 % | Heron Therapeutics, Inc.: Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance | Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF- (+27%) and APONVIE- (+50%)Q1 2026 total net revenue of $34.7 millionReached settlement with Baxter... ► Artikel lesen |
Das Unternehmen CORNERSTONE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CORNERSTONE THERAPEUTICS INC finden Sie auf Wallstreet Online.